APO Research
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

Selected research

Market Analysis & Forecast

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast 2026-2032

21 December 2025195 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

Read the full market overview

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

Report Includes

This report presents an overview of global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Amyotrophic Lateral Sclerosis (ALS) Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Amyotrophic Lateral Sclerosis (ALS) Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, projected growth trends, production technology, application and end-user industry.

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Company

Mitsubishi Tanabe Pharma

Sanofi

Mylan Pharma

Apotex

Glemark Generics

Covis Pharma

Sun Pharma

Lunan Pharma

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Amyotrophic Lateral Sclerosis (ALS) Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Riluzole Major Player Table 3. Edaravone (Radicava) Major Player Table 4. Other Major Player Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Drugs Store Major Player Table 8. Other Major Player Table 9. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends Table 10. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers Table 11. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges Table 12. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2021-2026) Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2027-2032) Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Headquarters & Area Served Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Product Type & Application Table 23. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2027-2032) Table 36. Mitsubishi Tanabe Pharma Company Information Table 37. Mitsubishi Tanabe Pharma Business Overview Table 38. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 40. Mitsubishi Tanabe Pharma Recent Development Table 41. Sanofi Company Information Table 42. Sanofi Business Overview Table 43. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 45. Sanofi Recent Development Table 46. Mylan Pharma Company Information Table 47. Mylan Pharma Business Overview Table 48. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 50. Mylan Pharma Recent Development Table 51. Apotex Company Information Table 52. Apotex Business Overview Table 53. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 55. Apotex Recent Development Table 56. Glemark Generics Company Information Table 57. Glemark Generics Business Overview Table 58. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 60. Glemark Generics Recent Development Table 61. Covis Pharma Company Information Table 62. Covis Pharma Business Overview Table 63. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 65. Covis Pharma Recent Development Table 66. Sun Pharma Company Information Table 67. Sun Pharma Business Overview Table 68. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 70. Sun Pharma Recent Development Table 71. Lunan Pharma Company Information Table 72. Lunan Pharma Business Overview Table 73. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 75. Lunan Pharma Recent Development Table 76. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 77. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 78. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 79. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 80. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026) & (US$ Million) Table 82. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (US$ Million) & (2027-2032) Table 83. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 86. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 87. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026) & (US$ Million) Table 89. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (US$ Million) & (2027-2032) Table 90. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 91. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 92. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 93. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 95. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 96. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 97. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (US$ Million) & (2021-2026) Table 100. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (US$ Million) & (2027-2032) Table 101. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 102. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 103. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 104. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 105. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026) & (US$ Million) Table 107. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (US$ Million) & (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Image Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Riluzole Image Figure 5. Edaravone (Radicava) Image Figure 6. Other Image Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Drugs Store Image Figure 11. Other Image Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032) Figure 25. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032) Figure 26. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Country (2021-2032) Figure 27. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032) Figure 44. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • Mylan Pharma
  • Apotex
  • Glemark Generics
  • Covis Pharma
  • Sun Pharma
  • Lunan Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Type
  3. 1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Riluzole
  5. 1.2.3 Edaravone (Radicava)
  6. 1.2.4 Other
  7. 1.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
  8. 1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Drugs Store
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
  1. 2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
  2. 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers
  3. 2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges
  4. 2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2021-2032)
  2. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
  3. 3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Players
  2. 4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Product Type & Application
  8. 4.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
  11. 4.6.3 2025 Amyotrophic Lateral Sclerosis (ALS) Treatment Tier 1, Tier 2, and Tier 3
5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  1. 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2021-2032)
6 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  1. 6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Mitsubishi Tanabe Pharma
  2. 7.1.1 Mitsubishi Tanabe Pharma Company Information
  3. 7.1.2 Mitsubishi Tanabe Pharma Business Overview
  4. 7.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  6. 7.1.5 Mitsubishi Tanabe Pharma Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Mylan Pharma
  14. 7.3.1 Mylan Pharma Company Information
  15. 7.3.2 Mylan Pharma Business Overview
  16. 7.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  18. 7.3.5 Mylan Pharma Recent Developments
  19. 7.4 Apotex
  20. 7.4.1 Apotex Company Information
  21. 7.4.2 Apotex Business Overview
  22. 7.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  24. 7.4.5 Apotex Recent Developments
  25. 7.5 Glemark Generics
  26. 7.5.1 Glemark Generics Company Information
  27. 7.5.2 Glemark Generics Business Overview
  28. 7.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  30. 7.5.5 Glemark Generics Recent Developments
  31. 7.6 Covis Pharma
  32. 7.6.1 Covis Pharma Company Information
  33. 7.6.2 Covis Pharma Business Overview
  34. 7.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  36. 7.6.5 Covis Pharma Recent Developments
  37. 7.7 Sun Pharma
  38. 7.7.1 Sun Pharma Company Information
  39. 7.7.2 Sun Pharma Business Overview
  40. 7.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  42. 7.7.5 Sun Pharma Recent Developments
  43. 7.8 Lunan Pharma
  44. 7.8.1 Lunan Pharma Company Information
  45. 7.8.2 Lunan Pharma Business Overview
  46. 7.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  48. 7.8.5 Lunan Pharma Recent Developments
8 North America
  1. 8.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2021-2032)
  2. 8.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country
  11. 8.6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2021-2032)
  2. 9.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country
  11. 9.6.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2021-2032)
  2. 10.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032)
  5. 10.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032)
  9. 10.5 China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2021-2032)
  2. 11.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country
  11. 11.6.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country
  11. 12.6.1 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst